8-K: Amwell Reports Q1 2024 Results, Reaffirms Full-Year Guidance

Amwell announced its first quarter 2024 financial results, highlighting progress in platform migration and sales transformation while reiterating its full-year guidance.

Summary

• Amwell reported a total revenue of $59.5 million for the first quarter of 2024.
• Subscription revenue reached $24.9 million, and Amwell Medical Group (AMG) visit revenue was $31.1 million.
• The company's gross margin was 31%.
• Net loss for the quarter was $73.4 million, compared to a $50.0 million loss in the previous quarter.
• Adjusted EBITDA was a loss of $45.7 million, compared to a loss of $36.9 million in the fourth quarter of 2023.
• Total visits were 1.7 million, with 68% of those visits occurring on the Converge platform.
• Amwell reaffirmed its 2024 guidance, projecting revenue between $259 and $269 million, AMG visits between 1.6 and 1.7 million, and adjusted EBITDA between a loss of $160 million and $155 million.
• The company also provided a preliminary 2025 outlook, estimating revenue between $335 and $350 million and adjusted EBITDA between a loss of $45 million and $35 million.
• Amwell aims to achieve adjusted EBITDA breakeven in 2026.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the increased losses and the ongoing challenges in achieving profitability, despite positive progress in platform migration and sales transformation. The reiterated guidance and 2025 outlook provide some optimism, but the current financial performance is concerning.

Positives

• Amwell is making progress in deploying its solution for the Military Health System.
• A significant portion of visit volume has been successfully migrated to the Converge platform.
• The company's sales transformation is expected to drive future growth.
• Amwell is optimizing its cost structure.
• The company has reiterated its 2024 guidance.
• The company has provided a preliminary 2025 outlook with improved revenue and adjusted EBITDA.
• The company is aiming for adjusted EBITDA breakeven in 2026.

Negatives

• The net loss for Q1 2024 was $73.4 million, which is higher than the $50.0 million loss in the previous quarter.
• Adjusted EBITDA was a loss of $45.7 million, which is worse than the $36.9 million loss in the previous quarter.
• The company is still operating at a significant loss.

Risks

• The company's ability to regain and maintain compliance with NYSE listing standards is a risk.
• There is a risk associated with the successful transition of clients to the Converge platform without significant attrition.
• The company faces risks related to renewing and upselling its client base.
• The continuation of the DHA relationship beyond July 2025 with comparable financial terms is not guaranteed.
• Weak growth and increased volatility in the telehealth market pose a risk.
• The company must adapt to rapid technological changes.
• Increased competition from existing and potential new participants in the healthcare industry is a risk.
• Changes in healthcare laws, regulations, or trends could impact the company.
• The company must comply with federal and state privacy regulations.
• A cybersecurity breach could result in significant liability.

Future Outlook

Amwell has provided 2024 revenue guidance between $259 and $269 million, AMG visits between 1.6 and 1.7 million, and adjusted EBITDA between a loss of $160 million and $155 million. The company also provided a preliminary 2025 outlook with revenue between $335 and $350 million and adjusted EBITDA between a loss of $45 million and $35 million, with a goal to reach adjusted EBITDA breakeven in 2026.

Management Comments

• Ido Schoenberg, M.D., chairman and CEO of Amwell, stated that the company made significant strides forward in Q1.
• Schoenberg noted the completion of critical milestones for the Military Health System deployment.
• Schoenberg highlighted the successful migration of visit volume onto the Converge platform.
• Schoenberg believes the sales transformation will return the company to growth.
• Schoenberg stated that the company is putting its re-platforming behind it and optimizing its cost structure.
• Schoenberg expressed growing conviction around the value delivered to clients and the aim to achieve profitable growth.

Industry Context

This announcement comes as the telehealth industry faces increased competition and scrutiny, with companies needing to demonstrate sustainable growth and profitability. Amwell's focus on platform migration and cost optimization aligns with the broader industry trend of seeking efficiency and scalability.

Comparison to Industry Standards

• Teladoc, a major competitor, reported Q1 2024 revenue of $646.1 million, significantly higher than Amwell's $59.5 million, but also reported a net loss of $82.7 million, indicating that profitability remains a challenge across the industry.
• Similar to Amwell, companies like Livongo (now part of Teladoc) have focused on platform integration and cost management to improve financial performance.
• The telehealth sector is seeing a shift towards hybrid care models, which Amwell is also pursuing with its Converge platform, aligning with industry trends.
• Amwell's gross margin of 31% is lower than some established players in the software and technology space, but is typical for companies in the healthcare services sector.

Related Party Transactions

• The document mentions related party transactions in accounts receivable and deferred revenue, but does not provide details of the nature of the transactions.

Stakeholder Impact

• Shareholders may be concerned about the increased losses, but may be encouraged by the long-term growth prospects.
• Employees may be affected by the ongoing cost optimization efforts.
• Customers may benefit from the improved platform and services.
• Suppliers and creditors may be impacted by the company's financial performance.

Next Steps

• Amwell will continue to deploy its solution for the Military Health System.
• The company will focus on migrating more clients to the Converge platform.
• Amwell will continue to optimize its cost structure.
• The company will work towards achieving adjusted EBITDA breakeven in 2026.

Key Dates

Keywords

telehealth, hybrid care, digital health, Amwell, Converge, financial results, EBITDA, revenue, healthcare, AMG